Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 4;30(6):oyaf143.
doi: 10.1093/oncolo/oyaf143.

Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors

Ziliang Zheng  1   2 , Zhu Shen  1   2
Affiliations

Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors

Ziliang Zheng et al. Oncologist. .

Abstract

Background: Immune checkpoint inhibitors (ICIs) have demonstrated significant therapeutic benefits but are also associated with skin-related adverse reactions. The specific characteristics of severe adverse reactions caused by ICIs remain unclear.

Objective: To investigate the disease characteristics of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)-like reactions induced by ICIs.

Methods: Cases of ICI-induced SJS/TEN were collected from PubMed, CNKI, Wanfang Data Knowledge Service Platform, and Guangdong Provincial People's Hospital, with a search time span ranging from March 2011 to January 31, 2024.

Results: A total of 110 cases of SJS, TEN, and overlapping SJS/TEN were analyzed, with a male predominance (62%). Mucous membrane involvement was observed in 71 patients (66%), though less frequently than in classic SJS/TEN. The mean latency period was 64 days, varying by subtype (105 days for SJS and 53 days for TEN). Combination therapy with ICIs was associated with a higher mortality risk (P = .029). Deceased patients exhibited shorter latency periods (mean 30.3 days) and more severe mucosal involvement (up to 100%), although the differences were not statistically significant. Systemic glucocorticoid therapy was the cornerstone of treatment for SJS/TEN-like reactions. The addition of immunoglobulin showed a trend toward improved outcomes but did not significantly affect mortality or cure rates compared to glucocorticoid monotherapy. The combination of systemic glucocorticoids and antibiotics demonstrated a promising trend, with a higher proportion of patients in the improvement/cure group using this regimen (P = .085).

Conclusions: This study summarizes the clinical characteristics of ICI-induced SJS/TEN-like reactions, providing insights into their features and potential treatment strategies for severe skin-related adverse events induced by ICIs.

Keywords: Stevens-Johnson syndrome; immune checkpoint inhibitors; immune-related adverse events; severe cutaneous adverse reactions; toxic epidermal necrolysis.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Maloney NJ, Ravi V, Cheng K, Bach DQ, Worswick S.. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol. 2020;59:e183-e188. https://doi.org/ 10.1111/ijd.14811 - DOI - PubMed
    1. Hasegawa A, Abe R.. Stevens-Johnson syndrome and toxic epidermal necrolysis: updates in pathophysiology and management. Chin Med J (Engl). 2024;137:2294-2307. https://doi.org/ 10.1097/CM9.0000000000003250 - DOI - PMC - PubMed
    1. Wang L, Varghese S, Bassir F, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front Med. 2022;9:949520. https://doi.org/ 10.3389/fmed.2022.949520 - DOI - PMC - PubMed
    1. Chen A, Kolodney JA, Kolodney MS.. Retrospective cohort study characterizing PD-1/PD-L1 checkpoint inhibition associated Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2024;91:948-949. https://doi.org/ 10.1016/j.jaad.2024.06.066 - DOI - PubMed
    1. Bray ER, Lin RR, Li JN, et al. Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases. Arch Dermatol Res. 2024;316:233. https://doi.org/ 10.1007/s00403-024-03061-6 - DOI - PubMed

Substances

LinkOut - more resources